Mouse Monoclonal ITGB7 Antibody

The ITGB7 antibody targets the integrin β7 subunit, a cell surface protein critical for mediating leukocyte adhesion and migration in mucosal and lymphoid tissues. Integrin β7 pairs with α4 or αE subunits to form heterodimers α4β7 and αEβ7. which bind to endothelial adhesion molecules (e.g., MAdCAM-1. E-cadherin) and facilitate lymphocyte trafficking to the gut-associated lymphoid tissue (GALT) and immune surveillance. α4β7 integrin, in particular, plays a key role in inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis by promoting T-cell infiltration into intestinal mucosa. ITGB7 antibodies, such as vedolizumab, block this interaction, reducing inflammation and serving as a therapeutic strategy for IBD. Research also links ITGB7 to immune responses in infections (e.g., HIV) and cancers (e.g., colorectal cancer), where its expression influences tumor progression or immune evasion. Structurally, ITGB7 contains a conserved integrin β-propeller domain and regulates intracellular signaling pathways, including cytoskeletal reorganization and survival signals. Studies on ITGB7 antibodies continue to explore their diagnostic potential in monitoring immune disorders and their therapeutic efficacy in autoimmune and oncologic contexts, highlighting their dual role as biomarkers and targeted biologics.